Radiolabelling: Zero friction. Maximum impact.

High‑performance radiochemistry

We deliver high‑purity radiolabelling, optimised formulations and decision‑ready QC data with speed, precision and reliability.

With access to a broad portfolio of alpha and beta emitters, advanced analytical platforms and fully integrated in vivo imaging in-house, we provide clean data, predictable timelines and a seamless end-to-end workflow.

What we deliver

Radiolabelling of small molecules, peptides, antibodies and biologics.
Chelator conjugation (DOTA, DFO, bifunctional chelators).
Established access to ²²⁵Ac, ²¹²Pb, ¹⁷⁷Lu, ⁸⁹Zr, ⁶⁸Ga, ¹⁸F, ⁹⁹mTc, ¹¹¹In, ¹⁶¹Tb, ⁶⁴Cu and ⁶⁷Cu.
High‑purity QC (HPLC/TLC), stability testing, immunoreactivity.
Formulation ready for in vivo studies.
Direct progression into PET, SPECT/CT, biodistribution and dosimetry.

One team. One workflow. One high standard of quality.

Why work with us?

In-house specialisms: Deep radiopharmaceutical biology expertise.
Built for reliability: Engineered workflows, protocol development and process delivery.
Integrated biology and imaging: Everything under one roof.
Regulatory ready: ISO 45001 certified, licensed for alpha & beta emitters and predictive human dosimetry from pre-clinical data.
Global credibility: Trusted by US and EU innovators. Our environment is built for regulatory credibility, whether your next step is the FDA, EMA or MHRA.
Trusted by innovators: Delivering data to secure investment, progress IND‑enabling studies and move confidently toward first‑in‑human trials.

If you need radiochemistry that scientifically underpins RPT development, come and speak to us.

World-class minds for RPT discovery and development

In the complex landscape of radiochemistry and translational imaging, the difference lies in the expertise behind the science.

Our team comprises industry-leading specialists across preclinical services and radiopharmaceuticals, dedicated to bridging the gap between early discovery and clinical success.

Meet the experts who turn sophisticated data into actionable therapeutic insights.

Explore our scientific expertise

Case study: Dual‑isotope radiolabelling to accelerate go/no‑go decisions

Brief: Dual‑isotope radiolabelling (¹⁷⁷Lu + ⁸⁹Zr), biodistribution and dosimetry to hit an investor milestone.

We delivered:

97% radiochemical purity.
Multi‑timepoint biodistribution.
PET/SPECT imaging and gamma counting.
Human organ dosimetry using clinical‑grade software.

Outcome: Investor round secured. Programme advanced. Timelines protected.

Start your project

Ready to accelerate your radiopharmaceutical programme?

Our experts are here to support your journey from concept to clinic. Contact our team to discuss a tailored solution.

Speak to the team, we’ll scope your project and get you moving fast.

Expertise in radiolabelling

With gamma, beta and alpha-emitting radiometals of small molecules (e.g., FAPI, PSMA), peptides, proteins and other biologics containing chelators such as DOTA, DOTAM, Macropa, and DFO/DFO*. Experience in a variety of purification methods (e.g., ultrafiltration, SPE), QC analysis (HPLC, ITLC, gamma spectrometry), and conjugation techniques.

Discover more